Vela Diagnostics receives BARDA funding to develop COVID-19 tests
FAIRFIELD, N.J., April 20, 2020 /PRNewswire/ --Vela Diagnostics has been awarded a $225,000 contract by the Biomedical Advanced Research and Development Authority (BARDA) part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop manual and automated tests to detect SARS-CoV-2, the virus that causes COVID-19.
The ViroKey™ SARS-CoV-2 RT-PCR Test is a probe-based reverse transcription PCR test that detects the virus by targeting conserved regions of the SARS-CoV-2 genome.
Under the agreement, Vela Diagnostics will perform verification and clinical validation of the ViroKey™ SARS-CoV-2 RT-PCR Test to be used on automated and manual workflows for Emergency Use Authorization (EUA) submission to the U.S. Food and Drug Administration (FDA). Support from BARDA is expected to accelerate the progress toward EUA submission.
The automated ViroKey™ SARS-CoV-2 RT-PCR Test is performed on a workflow consisting of the Sentosa™ SX101 instrument, in conjunction with the Applied Biosystems 7500 Fast Dx Real-Time (ABI 7500 Fast Dx) PCR instrument or the Sentosa™ SA201 instrument.
Up to 48 samples (including positive and negative controls) can be processed per run on the automated workflow. The manual assay was developed to enable flexible sample processing and quick adoption of the test by laboratories with existing ABI 7500 Fast Dx instruments.
High volume testing of SARS-CoV-2 is also critical in mitigating the rapidly evolving COVID-19 pandemic. The CDC recommends COVID-19 testing for individuals with symptoms associated with COVID-19 such as fever and acute respiratory illness.
"High throughput detection of SARS-CoV-2 using our automated workflow will provide rapid and valuable information to save lives," said Sam Dajani, acting CEO and chairman of the Board. "The funding from BARDA will enable Vela Diagnostics to increase the domestic and global testing capacity for COVID-19 to curb further spread of the virus."
"Rapid diagnostic tests put essential information into the hands of healthcare providers and patients to manage patient care safely and appropriately. Data gathered from high-throughput testing aids public health officials in making decisions about community mitigation to combat the pandemic," said BARDA Director Rick Bright, Ph.D.
To date, COVID-19 has affected 199 countries and territories around the world, with total cases exceeding a million in US, Europe and China combined and at least 100,000 fatalities worldwide. On March 11, the World Health Organization declared COVID-19 to be a pandemic.
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract No. 75A50120C00039.
About Vela Diagnostics
Vela Diagnostics is a leading provider of an automated IVD Next–Generation Sequencing (NGS) workflow in the global diagnostics market. VELA's real-time PCR and NGS applications are available on an integrated Sentosa™ platform; this provides a unique ability to leverage one system for two workflows, while carrying out tests for various targets in order to answer current clinical and research questions, as well as to drive laboratory operational efficiency.
All Sentosa™ products listed above are by Vela Diagnostics. For more information, visit www.veladx.com.
SOURCE Vela Diagnostics